: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disease. It is associated with mutations. Its main features are recurrent episodes of fever and serositis. Patients can display dermatological manifestations such as erysipelas-like erythema, generally considered as a neutrophilic dermatosis (ND). It has been suggested that FMF can be associated with other types of ND. Our aim was to perform a systematic review of the literature to assess the link between ND and FMF.: A systematic review of the literature was performed using MEDLINE from 1946 to 2018. Three independent investigators identified reports of non-erysipelas-like erythema neutrophilic dermatosis (NEND) associated with FMF, selected the criteria to establish the diagnosis of FMF and ND, and evaluated the link between the two conditions. FMF-associated NEND was supported by confirmation of both diagnoses and exclusion of other causes of ND.: Eighteen articles were selected. Nine articles reported FMF patients with the following NEND: neutrophilic panniculitis (n = 4), Sweet syndrome (n = 6), and pyoderma gangrenosum (n = 1). None of these cases was supported by histological confirmation, fulfilled diagnostic criteria for definitive or probable FMF, or confirmed the exclusion of all the most frequent diseases associated with NEND. As a result, there is insufficient evidence to support a potential relationship between NEND and FMF.: The association between FMF and NEND remains unclear. In FMF patients with NEND, every differential diagnosis and alternative cause of NEND should be excluded before drawing any conclusions about a potential causal relationship.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/03009742.2021.1904588 | DOI Listing |
J Coll Physicians Surg Pak
January 2025
Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a rare condition characterised by fever, leucocytosis, and painful skin lesions. This retrospective study analysed 21 patients with Sweet syndrome treated at the Affiliated Hospital of Xuzhou Medical University from January 2015 to June 2022. The study aimed to investigate the aetiology, clinicopathological features, and treatment outcomes.
View Article and Find Full Text PDFAdv Exp Med Biol
January 2025
Lester and Sue Smith Breast Center, Houston, TX, USA.
This chapter reviews tumor-associated myeloid cells, including macrophages, neutrophils, and other innate immune cells, and their multifaceted roles in supporting breast cancer progression and metastasis. In primary tumors, myeloid cells play key roles in promoting tumor epithelial-mesenchymal transition (EMT) and invasion. They can facilitate intravasation (entry into the bloodstream) and colonization, disrupting the endothelial cell layer and reshaping the extracellular matrix.
View Article and Find Full Text PDFJID Innov
March 2025
AMPEL BioSolutions LLC, Charlottesville, Virginia, USA.
Abnormalities in gene expression profiles characterize patients with inflammatory skin diseases, including psoriasis, and changes may reflect the action of specific therapeutic agents. To examine this, gene expression analysis of psoriatic skin was assessed by Gene Set Variation Analysis using informative gene modules, and longitudinal data were analyzed to assess the impact of various treatments. Ridge penalized logistic regression was employed to derive a transcriptomic score.
View Article and Find Full Text PDFF1000Res
January 2025
Department of Anatomy, Miyazaki University, Miyazaki, Miyazaki Prefecture, 889-1692, Japan.
This correspondence discusses the recent findings by Straalen et al., highlighting molecular similarities and distinctions between palmoplantar pustulosis (PPP) and dyshidrotic palmoplantar eczema (DPE). The study emphasizes shared proinflammatory pathways and T-cell-related gene upregulation while detailing unique features such as neutrophil involvement in PPP and lipid antigen processing in DPE.
View Article and Find Full Text PDFIL-17 and IL-23 inhibitors have shown successful results in improving skin lesions in the treatment of moderate-to-severe plaque psoriasis. However, psoriasis is a chronic inflammatory disease characterized by systemic inflammation including joints in addition to skin lesions. Therefore, in this retrospective and observational cohort study, we aimed to evaluate the effect of IL-17 inhibitors (secukinumab and ixekizumab) and IL-23 inhibitors (risankizumab and guselkumab) on systemic inflammation in psoriasis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!